NCT04285268 2026-01-30
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03884972 2023-09-25
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04990778 2022-03-10
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03343678 2018-01-09
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
Boehringer Ingelheim
Phase 1 Withdrawn
NCT02640833 2016-07-26
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
AbbVie
Phase 1 Withdrawn
NCT02095574 2014-08-13
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
AbbVie
Phase 1 Withdrawn
NCT01969682 2014-05-26
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
AbbVie
Phase 1 Withdrawn